WuXi Biologics Achieves EcoVadis Platinum Medal for Sustainability for Third Year
WuXi Biologics Achieves EcoVadis Platinum Medal for Sustainability for Third Year
WuXi Biologics, a major player in the contract research and manufacturing sector, proudly announced that it has been awarded the EcoVadis Platinum Medal for sustainability for the third consecutive year. This prestigious recognition places WuXi among the top 1% of over 150,000 companies globally assessed by EcoVadis, which is renowned for evaluating corporate sustainability through a rigorous framework of 21 criteria encompassing four primary areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.
What the EcoVadis Platinum Medal Represents
This medal is not merely an accolade; rather, it serves as a testament to WuXi Biologics' unwavering commitment to comprehensive sustainability. The Platinum Medal reflects effective policies, diligent implementation strategies, and verifiable performance results that have been validated by industry experts and external stakeholders. As organizations increasingly face pressure to implement effective environmental, social, and governance (ESG) practices, WuXi’s achievement highlights its proactive approach to these critical issues.
Key Initiatives Driving WuXi Biologics' Sustainability Efforts
WuXi Biologics has continuously worked to enhance its sustainability metrics across EcoVadis’ assessment areas. Here are some highlights of recent initiatives:
1. Science Based Targets initiative (SBTi) Approvals
WuXi Biologics has had its near-term and net-zero greenhouse gas emissions reduction targets officially approved by the SBTi. This initiative positions WuXi as one of the pioneers in its industry to receive such approvals, cementing its leadership role in ecological sustainability.
2. Green CRDMO White Paper
The company has also published a comprehensive Green CRDMO White Paper. This document aims to catalyze sustainable practices within the biologics sector, showcasing the company's advancement in green innovation technologies spanning research, development, and manufacturing. It highlights substantial carbon emission reductions achieved through eco-friendly operations and includes 242 case studies of energy-saving strategies across various scenarios, energy systems, and technology applications.
3. ISO 20400 Certification
WuXi Biologics achieved ISO 20400 certification for sustainable procurement, adhering to internationally recognized standards that advocate for the integration of sustainability principles within procurement processes. This certification promotes transparency and accountability throughout the supply chain, further enhancing WuXi's commitment to responsible sourcing.
Leadership's Perspective on Sustainability
Dr. Chris Chen, CEO of WuXi Biologics and Chair of the ESG Committee, expressed immense pride in receiving the Platinum Medal for a third consecutive year. He stated, "This accolade underscores our dedication to enhancing sustainability capabilities. As a global leader in Green CRDMO, we are committed to advancing ESG excellence and working alongside our partners to achieve their sustainability objectives."
A Vision for Long-term Value Creation
The consistent recognition through the EcoVadis Platinum Medal significantly boosts client confidence in WuXi Biologics' commitment to responsibility, innovative thinking, and industry-leading sustainability practices. In an evolving landscape where ESG compliance is crucial, the company adheres to the highest standards of quality and sustainability for enduring partnerships.
WuXi Biologics actively participates in major sustainability initiatives, including the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI). Its string of accolades includes an MSCI AAA rating, inclusion in the Dow Jones Sustainability Indices (DJSI), and recognition on the CDP’s 'A List' for both Climate Change and Water Security.
In addition to these, WuXi Biologics has been rated as a Sustainalytics industry leader for five consecutive years and has earned spots on prestigious indices like the FTSE4Good Index Series and the Hang Seng ESG 50 Index.
About WuXi Biologics
As a foremost global Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi Biologics (stock code 2269.HK) offers extensive solutions facilitating partners in the discovery, development, and manufacturing of biologics. With more than 12,000 devoted professionals distributed across countries, including the U.S., China, Germany, Ireland, Singapore, and Qatar, WuXi Biologics supports various integrated client projects, underscoring its commitment to health innovations.
By embracing environmental, social, and governance (ESG) responsibilities as integral to their ethos, WuXi Biologics continuously strives to set benchmarks within the biologics CRDMO industry. To explore more about their sustainability efforts and innovations in biologics, visit WuXi Biologics.
Topics General Business）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.